Clik here to view.
Pharmapack Europe 2025: Eco barrier packaging to launch
LOG Pharma Primary Packaging is set to present its new barrier eco line at Pharmapack Europe 2025. The new bottles for pharmaceuticals offer optimal oxygen scavenging. “Our R&D team has developed a...
View ArticleClik here to view.
Targeting ovarian cancer with a novel antibody therapeutic
What is Elahere® (mirvetuximab soravtansine) and what makes it unique as a medicine for ovarian cancer? Elahere is the first and only novel therapy approved in the EU for patients with folate receptor...
View ArticleClik here to view.
Legislative milestone for UK clinical trials
New legislation is set to facilitate a “more efficient, streamlined and adaptable regulatory framework” for UK clinical trials, according to the Medicines and Healthcare products Regulatory Agency...
View ArticleClik here to view.
Innovative biologic prefilled syringe approved in EU
The European Medicines Agency (EMA) has approved Roche’s Vabysmo ® (faricimab) prefilled syringe (PFS) as the EU’s first and only bispecific antibody prefilled syringe for retinal conditions causing...
View ArticleClik here to view.
Novo Nordisk investing in rare disease with major new manufacturing site
Novo Nordisk is planning a new investment, which marks the first time this millennium that the pharmaceutical company breaks ground in Denmark by establishing a new production site. A total of DKK 8.5...
View ArticleClik here to view.
CHMP recommends novel long-acting HIV treatment
The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion for a marketing authorisation to approve the first complete long-acting regimen to treat HIV. The regimen...
View ArticleClik here to view.
Antibody drug has promise as “next frontier” in inflammatory bowel disease
The first randomised, placebo-controlled study to evaluate the impact of an anti-TL1A monoclonal antibody (mAb) in Crohn’s disease has demonstrated for high dose the highest achieved primary endpoint...
View ArticleClik here to view.
Adopting AI for R&D in 2025 – what needs to be addressed?
With the life sciences and healthcare sectors increasing integration of artificial intelligence (AI) into their infrastructure, according to research by GlobalData, one-third of healthcare...
View ArticleClik here to view.
Early allogeneic cell therapy trial results offer hope for sight condition
New topline Phase I/II data show that an allogeneic cell therapy could help restore vision in individuals with corneal oedema secondary to corneal endothelial dysfunction. AURN001 combines allogeneic...
View ArticleClik here to view.
Bristol Myers Squibb licenses amyloid-beta antibody programme
Bristol Myers Squibb has licensed an amyloid-beta antibody programme from BioArctic AB. The PyroGlutamate-amyloid-beta (PyroGlu-Aβ) programme includes novel antibodies (BAN1503 and BAN2803). These...
View Article